title: Light-induced changes in glutamate release from isolated rat retina is regulated by cyclic guanosine monophosphate.
abstract: Isolated rat retina was preloaded with [(14)C]glutamate and subsequently superfused to follow release of glutamate (Glu). After 20 min of superfusion in the dark, exposure of the [(14)C]Glu preloaded rat retina to a single train of white light pulses reduced Glu efflux significantly in the absence as well as in the presence of low (4 microM) and high (0.5 mM) concentrations of the Glu uptake inhibitor trans-L-pyrrolidine-2,4-dicarboxylate (t-PDC). The dark-light response was the highest in the presence of 4 microM t-PDC by establishing a plateau at 75% +/- 7% of the tonic Glu release in the dark (100%). Displaying transient to saturating responses with increasing relative luminance, time series of four trains of white light pulses arrived at a plateau of 85% +/- 10%. The cyclic guanosine monophosphate (cGMP) phosphodiesterase inhibitor Zaprinast (200 microM) antagonized the effect of the light series, leading to a plateau of 115% +/- 9%. Exposure of the retina to the guanylyl cyclase inhibitor LY83583 (30 and 100 microM) showed fast, transient responses characterized by peaks at 90% +/- 1% and 80% +/- 3%, respectively.
authors.affiliation: Department of Neurochemistry, Insitute of Chemistry, Chemical Research Center, Hungarian Academy of Sciences, Budapest, Hungary.
authors.forename: Péter
authors.initials: P
authors.lastname: Barabás
authors.forename: Ilona
authors.initials: I
authors.lastname: Kovács
authors.forename: Richárd
authors.initials: R
authors.lastname: Kovács
authors.forename: János
authors.initials: J
authors.lastname: Pálhalmi
authors.forename: Julianna
authors.initials: J
authors.lastname: Kardos
authors.forename: Arne
authors.initials: A
authors.lastname: Schousboe
mesh_terms: D000634:Aminoquinolines / Q000494:pharmacology; D000818:Animals; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics; D006152:Cyclic GMP / Q000378:metabolism*; D003623:Dark Adaptation / Q000187:drug effects / Q000502:physiology; D003998:Dicarboxylic Acids / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018698:Glutamic Acid / Q000378:metabolism* / Q000493:pharmacokinetics; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology; D009924:Organ Culture Techniques; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010775:Photic Stimulation; D011688:Purinones / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D020318:Rats, Long-Evans; D012160:Retina / Q000187:drug effects / Q000378:metabolism*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*; D014785:Vision, Ocular / Q000187:drug effects / Q000502:physiology*
chemical_list: D000634:Aminoquinolines; D002250:Carbon Radioisotopes; D003998:Dicarboxylic Acids; D004791:Enzyme Inhibitors; D014179:Neurotransmitter Uptake Inhibitors; D010726:Phosphodiesterase Inhibitors; D011688:Purinones; D011759:Pyrrolidines; D018698:Glutamic Acid; C041715:6-anilino-5,8-quinolinedione; C083486:pyrrolidine-2,4-dicarboxylic acid; C011145:zaprinast; D006152:Cyclic GMP